Bluebird's catalysts in 2015
CNBC Videos by CNBC Videos 2:14 mins
Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders,and sickle cell anemia.
Conatus announces results from three clinical trials »Top-line results from ACLF and Organ Impairmentclinical trials of Emricasan
BCLI: Brainstorm Takes Major Leap Forward In Battle vs. ALS
Zacks Small Cap Research
By Zacks Small Cap Research 18 minutes ago
We remain upbeat on the Brainstorm story, and nothing reported from the Phase 2a trial has altered our impression of the company or the potential for NurOwn™. Thus, we are reiterating our ‘Buy’ rating and maintaining a $10 price target.
shorts will be buried
have to be insane
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015
"The interim analysis of this study, and results of our prior phase 1/2 study, have shown that a single
dose of NurOwn™ is safe and can provide clinically meaningful benefits to ALS patients, such as a reduction in the rate of progression, and actual improvements in function," Fiorino continued.
THIS GIVES YOU AN IDEA HOW GREAT DATA WILL BE :
October 7, 2014
BrainStorm Cell Therapeutics Inc. October 7, 2014 7:07 AM
"We are pleased that the FDA has granted Fast Track status for NurOwn™ as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm."Weexpect Fast Track designation, which recognizes the potential of NurOwn™ as to address an unmet medical need in ALS, to help speed and improve our development program